WallStSmart

Edwards Lifesciences Corp (EW)vsQMMM Holdings Limited Ordinary Shares (QMMM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 335854% more annual revenue ($6.30B vs $1.88M). EW leads profitability with a 17.4% profit margin vs -150.1%. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

QMMM

Avoid

14

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 4.39
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.7%)

Margin of Safety

+69.7%

Fair Value

$261.90

Current Price

$79.96

$181.94 discount

UndervaluedFair: $261.90Overvalued

Intrinsic value data unavailable for QMMM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

QMMM2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.3910/10

Safe zone — low bankruptcy risk

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
44.7x2/10

Premium valuation, high expectations priced in

Free Cash FlowQuality
$-21.10M2/10

Negative free cash flow — burning cash

QMMM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
519.1x2/10

Trading at 519.1x book value

Return on EquityProfitability
-198.1%2/10

ROE of -198.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : QMMM

The strongest argument for QMMM centers on Debt/Equity, Altman Z-Score.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.

Bear Case : QMMM

The primary concerns for QMMM are EPS Growth, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

EW profiles as a growth stock while QMMM is a turnaround play — different risk/reward profiles.

EW is growing revenue faster at 16.7% — sustainability is the question.

QMMM generates stronger free cash flow (-51,742), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EW scores higher overall (61/100 vs 14/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

QMMM Holdings Limited Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

QMMM Holdings Limited, provides digital media advertising and marketing production services primarily in Hong Kong.

Visit Website →

Want to dig deeper into these stocks?